Does Pentraxin-3 contribute to the reduction of low-density lipoprotein levels by statin therapy?

Oxidized Low Density Lipoprotein, Statin Therapy and Carotid Stenosis

The future of low-density lipoprotein cholesterol lowering therapy: An end to statin exceptionalism?

A screen of microbial culture broths led by Akira Endo in the 1970s led to the discovery of compactin, a competitive inhibitor of the rate-limiting enzyme in cholesterol synthesis HMG-CoA reductase (HMGCR). Subsequent development of closely related compounds gave rise to statin medications. Numerous clinical trials of statin therapy demonstrate robust reductions in both low-density lipoprotein ...

Does Nitric Oxide Generated by Dendritic Cells Contribute to the Low Incidence of GVHD after Cord Blood Transplantation?

Statin use in patients with extremely low low-density lipoprotein levels is associated with improved survival.

BACKGROUND Aggressive lipid management has recently become the standard of care for patients with coronary heart disease. The safety and effectiveness of statin usage for patients with extremely low low-density lipoprotein (LDL) levels are less clear, however. The aim of this study was to investigate the safety and clinical outcomes of statin treatment in patients with LDL cholesterol levels be...

Pharmacogenetic predictors of statin-mediated low-density lipoprotein cholesterol reduction and dose response.

BACKGROUND There is interindividual variation in low-density lipoprotein cholesterol (LDLc) lowering by statins and limited study into the genetic associations of the dose dependant LDLc lowering by statins. METHODS AND RESULTS Five hundred nine patients with hyperlipidemia were randomly assigned atorvastatin 10 mg, simvastatin 20 mg, or pravastatin 10 mg (low-dose phase) followed by 80 mg, 8...